Groowe Groowe / Newsroom / QNTM
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

QNTM News

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

globenewswire.com
QNTM

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

globenewswire.com
QNTM

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

accessnewswire.com
QNTM

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

globenewswire.com
QNTM

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

globenewswire.com
QNTM

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

globenewswire.com
QNTM

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

globenewswire.com
QNTM